The 677C>T mutation of the MTHFR gene increases the risk of venous thromboembolism in koreans and a meta-analysis from asian population

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 3, 2013, Pages 309-314

  Jang, Moon Ju ^a   Jeon, Young Joo ^a   Choi, Won Il ^b   Choi, Yi Seul ^a   Kim, Su Yeoun ^a   Chong, So Young ^a   Oh, Doyeun ^a   Kim, Nam Keun ^a  

^a CHA University   (South Korea)

^b Keimyung University   (South Korea)

Author keywords

1298A> C; 677C> T; methylenetetrahydrofolate reductase; venous thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; ARTICLE; ASIAN; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

1298A> C; 677C> T; METHYLENETETRAHYDROFOLATE REDUCTASE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; RISK; VENOUS THROMBOEMBOLISM;

EID: 84878892613     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612436677     Document Type: Article

References (20)

1. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A. 2001 ; 98 ((26)). 14853-14858
2. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 ; 10 ((1)). 111-113
3. van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet. 1998 ; 62 ((5)). 1044-1051
4. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998 ; 98 ((23)). 2520-2526
5. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988 ; 43 ((4)). 414-421
6. De Marco P, Calevo MG, Moroni A, et al. Polymorphisms in genes involved in folate metabolism as risk factors for NTDs. Eur J Pediatr Surg. 2001 ; 11 ((suppl 1)). S14 - S17
7. De Marco P, Calevo MG, Moroni A, et al. Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population. J Hum Genet. 2002 ; 47 ((6)). 319-324
8. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005 ; 3 ((2)). 292-299
9. Fujimura H, Kawasaki T, Sakata T, et al. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thromb Res. 2000 ; 98 ((1)). 1-8
10. Lin JS, Shen MC, Tsai W, Lin B. The prevalence of C677T mutation in the methylenetetrahydrofolate reductase gene and its association with venous thrombophilia in Taiwanese Chinese. Thromb Res. 2000 ; 97 ((3)). 89-94
11. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol. 2000 ; 109 ((4)). 870-874
12. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986 ; 77 ((6)). 1909-1916
13. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991 ; 88 ((6)). 1906-1914
14. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993 ; 92 ((3)). 1381-1386
15. Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem. 1998 ; 273 ((16)). 9987-9993
16. Cattaneo M, Tsai MY, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V: Q506). Arterioscler Thromb Vasc Biol. 1997 ; 17 ((9)). 1662-1666
17. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C - >T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002 ; 288 ((16)). 2023-2031
18. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998 ; 64 ((3)). 169-172
19. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis. 2002 ; 13 ((5)). 423-431
20. Naushad S, Jamal NJ, Angalena R, Prasad CK, Devi AR. Hyperhomocysteinemia and the compound heterozygous state for methylene tetrahydrofolate reductase are independent risk factors for deep vein thrombosis among South Indians. Blood Coagul Fibrinolysis. 2007 ; 18 ((2)). 113-117